[1] Laghouati E, Studer F, Depaulis A, Guillemain I. Early alterations of the neuronal network processing whisker-related sensory signal during absence epileptogenesis[J]. Epilepsia, 2022, 63:497-509. [2] Park DK, Kim W, Thornburg OS, McBrian DK, McKhann GM, Feldstein NA, Maddocks AB, Gonzalez E, Shen MY, Akman C, Provenzano FA. Convolutional neural network-aided tuber segmentation in tuberous sclerosis complex patients correlates with electroencephalogram[J]. Epilepsia, 2022, 63:1530-1541. [3] Neal A, Bouet R, Lagarde S, Ostrowsky-Coste K, Maillard L, Kahane P, Touraine R, Catenoix H, Montavont A, Isnard J, Arzimanoglou A, Hermier M, Guenot M, Bartolomei F, Rheims S, Jung J. Epileptic spasms are associated with increased stereo-electroencephalography derived functional connectivity in tuberous sclerosis complex[J]. Epilepsia, 2022, 63:2359-2370. [4] Boulogne S, Pizzo F, Chatard B, Roehri N, Catenoix H, Ostrowsky-Coste K, Giusiano B, Guenot M, Carron R, Bartolomei F, Rheims S. Functional connectivity and epileptogenicity of nodular heterotopias:a single-pulse stimulation study[J]. Epilepsia, 2022, 63:961-973. [5] Fleury M, Buck S, Binding LP, Caciagli L, Vos SB, Winston GP, Thompson PJ, Koepp MJ, Duncan JS, Sidhu MK. Episodic memory network connectivity in temporal lobe epilepsy[J]. Epilepsia, 2022, 63:2597-2622. [6] Li R, Deng C, Wang X, Zou T, Biswal B, Guo D, Xiao B, Zhang X, Cheng JL, Liu D, Yang M, Chen H, Wu Q, Feng L. Interictal dynamic network transitions in mesial temporal lobe epilepsy[J]. Epilepsia, 2022, 63:2242-2255. [7] Wirrell EC, Nabbout R, Scheffer IE, Alsaadi T, Bogacz A, French JA, Hirsch E, Jain S, Kaneko S, Riney K, Samia P, Snead OC, Somerville E, Specchio N, Trinka E, Zuberi SM, Balestrini S, Wiebe S, Cross JH, Perucca E, Moshé SL, Tinuper P. Methodology for classification and definition of epilepsy syndromes with list of syndromes:report of the ILAE Task Force on Nosology and Definitions[J]. Epilepsia, 2022, 63:1333-1348. [8] Zuberi SM, Wirrell E, Yozawitz E, Wilmshurst JM, Specchio N, Riney K, Pressler R, Auvin S, Samia P, Hirsch E, Galicchio S, Triki C, Snead OC, Wiebe S, Cross JH, Tinuper P, Scheffer IE, Perucca E, Moshé SL, Nabbout R. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants:position statement by the ILAE Task Force on Nosology and Definitions[J]. Epilepsia, 2022, 63:1349-1397. [9] Specchio N, Wirrell EC, Scheffer IE, Nabbout R, Riney K, Samia P, Guerreiro M, Gwer S, Zuberi SM, Wilmshurst JM, Yozawitz E, Pressler R, Hirsch E, Wiebe S, Cross HJ, Perucca E, Moshé SL, Tinuper P, Auvin S. International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood:position paper by the ILAE Task Force on Nosology and Definitions[J]. Epilepsia, 2022, 63:1398-1442. [10] Riney K, Bogacz A, Somerville E, Hirsch E, Nabbout R, Scheffer IE, Zuberi SM, Alsaadi T, Jain S, French J, Specchio N, Trinka E, Wiebe S, Auvin S, Cabral-Lim L, Naidoo A, Perucca E, Moshé SL, Wirrell EC, Tinuper P. International League Against Epilepsy classification and definition of epilepsy syndromes with onset at a variable age:position statement by the ILAE Task Force on Nosology and Definitions[J]. Epilepsia, 2022, 63:1443-1474. [11] Hirsch E, French J, Scheffer IE, Bogacz A, Alsaadi T, Sperling MR, Abdulla F, Zuberi SM, Trinka E, Specchio N, Somerville E, Samia P, Riney K, Nabbout R, Jain S, Wilmshurst JM, Auvin S, Wiebe S, Perucca E, Moshé SL, Tinuper P, Wirrell EC. ILAE definition of the idiopathic generalized epilepsy syndromes:position statement by the ILAE Task Force on Nosology and Definitions[J]. Epilepsia, 2022, 63:1475-1499. [12] Leal-Pardinas F, Truty R, McKnight DA, Johnson B, Morales A, Bristow SL, Yar Pang T, Cohen-Pfeffer J, Izzo E, Sankar R, Koh S, Wirrell EC, Millichap JJ, Aradhya S. Value of genetic testing for pediatric epilepsy:driving earlier diagnosis of ceroid lipofuscinosis type 2 Batten disease[J]. Epilepsia, 2022, 63:e68-73. [13] Hammer MF, Pan Y, Cumbay M, Pendziwiat M, Afawi Z, Goldberg-Stern H, Johnstone L, Helbig I, Cummins TR. Whole exome sequencing and co-expression analysis identify an SCN1A variant that modifies pathogenicity in a family with genetic epilepsy and febrile seizures plus[J]. Epilepsia, 2022, 63:1970-1980. [14] Ahn SJ, Oh J, Kim DY, Son H, Hwang S, Shin HR, Kim EY, Lee HS, Lee WJ, Moon J, Lee ST, Jung KH, Park KI, Jung KY, Lee S, Yu KS, Chu K, Lee SK. Effects of CYP2C19 genetic polymorphisms on the pharmacokinetics of lacosamide in Korean patients with epilepsy[J]. Epilepsia, 2022, 63:2958-2969. [15] Coombs ID, Ziobro J, Krotov V, Surtees TL, Cull-Candy SG, Farrant M. A gain-of-function GRIA2 variant associated with neurodevelopmental delay and seizures:functional characterization and targeted treatment[J]. Epilepsia, 2022, 63:e156-163. [16] Maillard PY, Baer S, Schaefer É, Desnous B, Villeneuve N, Lépine A, Fabre A, Lacoste C, El Chehadeh S, Piton A, Porter LF, Perriard C, Wardé MA, Spitz MA, Laugel V, Lesca G, Putoux A, Ville D, Mignot C, Héron D, Nabbout R, Barcia G, Rio M, Roubertie A, Meyer P, Paquis-Flucklinger V, Patat O, Lefranc J, Gerard M, de Bellescize J, Villard L, De Saint Martin A, Milh M; Epigen Consortium. Molecular and clinical descriptions of patients with GABAA receptor gene variants (GABRA1, GABRB2, GABRB3, GABRG2):a cohort study, review of literature, and genotype-phenotype correlation[J]. Epilepsia, 2022, 63:2519-2533. [17] Striano P, Auvin S, Collins A, Horvath R, Scheffer IE, Tzadok M, Miller I, Kay Koenig M, Lacy A, Davis R, Garcia-Cazorla A, Saneto RP, Brandabur M, Blair S, Koutsoukos T, De Vivo D. A randomized, double-blind trial of triheptanoin for drug-resistant epilepsy in glucose transporter 1 deficiency syndrome[J]. Epilepsia, 2022, 63:1748-1760. [18] Mullan KA, Anderson A, Shi YW, Ding JH, Ng CC, Chen Z, Baum L, Cherny S, Petrovski S, Sham PC, Lim KS, Liao WP, Kwan P. Potential role of regulatory DNA variants in modifying the risk of severe cutaneous reactions induced by aromatic anti-seizure medications[J]. Epilepsia, 2022, 63:936-949. [19] Halliday A, Duncan A, Cheung M, Boston RC, Apiwattanakul M, Camacho X, Bowden S, D'Souza W. Second-line immunotherapy and functional outcomes in autoimmune encephalitis:a systematic review and individual patient data meta-analysis[J]. Epilepsia, 2022, 63:2214-2224. [20] Makridis KL, Friedo AL, Kellinghaus C, Losch FP, Schmitz B, Boßelmann C, Kaindl AM. Successful treatment of adult Dravet syndrome patients with cenobamate[J]. Epilepsia, 2022, 63:e164-171. [21] Gataullina S, Galvani G, Touchet S, Nous C, Lemaire É, Laschet J, Chiron C, Dulac O, Dossi E, Brion JD, Messaoudi S, Alami M, Huberfeld G. GluN2C selective inhibition is a target to develop new antiepileptic compounds[J]. Epilepsia, 2022, 63:2911-2924. [22] Hahn CD, Jiang Y, Villanueva V, Zolnowska M, Arkilo D, Hsiao S, Asgharnejad M, Dlugos D. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTR)[J]. Epilepsia, 2022, 63:2671-2683. [23] Hurley EN, Ellaway CJ, Johnson AM, Truong L, Gordon R, Galettis P, Martin JH, Lawson JA. Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome:a phase 1 clinical trial[J]. Epilepsia, 2022, 63:1736-1747. [24] Riban V, Heulard I, Reversat L, Si Hocine H, Verleye M. Stiripentol inhibits spike-and -wave discharges in animal models of absence seizures:a new mechanism of action involving T-type calcium channels[J]. Epilepsia, 2022, 63:1200-1210. [25] Wu JY, Cock HR, Devinsky O, Joshi C, Miller I, Roberts CM, Sanchez-Carpintero R, Checketts D, Sahebkar F. Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex:post hoc analysis of randomized controlled phase 3 trial GWPCARE6[J]. Epilepsia, 2022, 63:1189-1199. [26] Schoonjans AS, Roosens L, Dewals W, Paelinck BP, Ceulemans B. Therapeutic drug monitoring of fenfluramine in clinical practice:pharmacokinetic variability and impact of concomitant antiseizure medications[J]. Epilepsia, 2022, 63:686-696. [27] Kahlig KM, Scott L, Hatch RJ, Griffin A, Martinez Botella G, Hughes ZA, Wittmann M. The novel persistent sodium current inhibitor PRAX-562 has potent anticonvulsant activity with improved protective index relative to standard of care sodium channel blockers[J]. Epilepsia, 2022, 63:697-708. [28] Najm I, Lal D, Alonso Vanegas M, Cendes F, Lopes-Cendes I, Palmini A, Paglioli E, Sarnat HB, Walsh CA, Wiebe S, Aronica E, Baulac S, Coras R, Kobow K, Cross JH, Garbelli R, Holthausen H, Rössler K, Thom M, El-Osta A, Lee JH, Miyata H, Guerrini R, Piao YS, Zhou D, Blümcke I. The ILAE consensus classification of focal cortical dysplasia:an update proposed by an ad hoc task force of the ILAE diagnostic methods commission[J]. Epilepsia, 2022, 63:1899-1919. [29] Jehi L, Jette N, Kwon CS, Josephson CB, Burneo JG, Cendes F, Sperling MR, Baxendale S, Busch RM, Triki CC, Cross JH, Ekstein D, Englot DJ, Luan G, Palmini A, Rios L, Wang X, Roessler K, Rydenhag B, Ramantani G, Schuele S, Wilmshurst JM, Wilson S, Wiebe S. Timing of referral to evaluate for epilepsy surgery:Expert Consensus Recommendations from the Surgical Therapies Commission of the International League Against Epilepsy[J]. Epilepsia, 2022, 63:2491-2506. [30] Varatharajah Y, Joseph B, Brinkmann B, Morita-Sherman M, Fitzgerald Z, Vegh D, Nair D, Burgess R, Cendes F, Jehi L, Worrell G. Quantitative analysis of visually reviewed normal scalp EEG predicts seizure freedom following anterior temporal lobectomy[J]. Epilepsia, 2022, 63:1630-1642. [31] Sinclair B, Cahill V, Seah J, Kitchen A, Vivash LE, Chen Z, Malpas CB, O'Shea MF, Desmond PM, Hicks RJ, Morokoff AP, King JA, Fabinyi GC, Kaye AH, Kwan P, Berkovic SF, Law M, O'Brien TJ. Machine learning approaches for imaging-based prognostication of the outcome of surgery for mesial temporal lobe epilepsy[J]. Epilepsia, 2022, 63:1081-1092. [32] Klodowski DA, George BJ, Sperling MR. Seizure latency and epilepsy localization as predictors of recurrence following epilepsy surgery[J]. Epilepsia, 2022, 63:1074-1080. [33] Yossofzai O, Fallah A, Maniquis C, Wang S, Ragheb J, Weil AG, Brunette-Clement T, Andrade A, Ibrahim GM, Mitsakakis N, Widjaja E. Development and validation of machine learning models for prediction of seizure outcome after pediatric epilepsy surgery[J]. Epilepsia, 2022, 63:1956-1969. [34] Castro-Villablanca F, Moeller F, Pujar S, D'Arco F, Scott RC, Tahir MZ, Tisdall M, Cross JH, Eltze C. Seizure outcome determinants in children after surgery for single unilateral lesions on magnetic resonance imaging:role of preoperative ictal and interictal electroencephalography[J]. Epilepsia, 2022, 63:3168-3179. [35] Johnson KJ, Moy B, Rensing N, Robinson A, Ly M, Chengalvala R, Wong M, Galindo R. Functional neuropathology of neonatal hypoxia-ischemia by single-mouse longitudinal electroencephalography[J]. Epilepsia, 2022, 63:3037-3050. [36] Lin JR, Cheng JF, Liu YT, Hsu TR, Lin KM, Chen C, Lin CL, Tsai MH, Tsai JW. Novel lissencephaly-associated DCX variants in the C-terminal DCX domain affect microtubule binding and dynamics[J]. Epilepsia, 2022, 63:1253-1265. [37] Nagib MM, Zhang S, Yasmen N, Li L, Hou R, Yu Y, Boda VK, Wu Z, Li W, Jiang J. Inhibition of TRPC3 channels by a novel pyrazole compound confers antiseizure effects[J]. Epilepsia, 2022, 63:1003-1015. [38] Kovermann P, Kolobkova Y, Franzen A, Fahlke C. Mutations associated with epileptic encephalopathy modify EAAT2 anion channel function[J]. Epilepsia, 2022, 63:388-401. [39] Astner-Rohracher A, Zimmermann G, Avigdor T, Abdallah C, Barot N, Brázdil M, Doležalová I, Gotman J, Hall JA, Ikeda K, Kahane P, Kalss G, Kokkinos V, Leitinger M, Mindruta I, Minotti L, Mizera MM, Oane I, Richardson M, Schuele SU, Trinka E, Urban A, Whatley B, Dubeau F, Frauscher B. Development and validation of the 5-SENSE score to predict focality of the seizure-onset zone as assessed by stereoelectroencephalography[J]. JAMA Neurol, 2022, 79:70-79. [40] Chen Z, Maturana MI, Burkitt AN, Cook MJ, Grayden DB. High-frequency oscillations in epilepsy:what have we learned and what needs to be addressed[J]. Neurology, 2021, 96:439-448. [41] Pennell PB, Karanam A, Meador KJ, Gerard E, Kalayjian L, Penovich P, Matthews A, McElrath TM, Birnbaum AK; MONEAD Study Group. Antiseizure medication concentrations during pregnancy:results from the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) study[J]. JAMA Neurol, 2022, 79:370-379. [42] Li Y, Meador KJ. Epilepsy and pregnancy[J]. Continuum (Minneap Minn), 2022, 28:34-54. [43] Henson T, Rawanduzy C, Salazar M, Sebastian A, Weber H, Al-Mufti F, Mayer SA. Outcome and prognostication after cardiac arrest[J]. Ann NY Acad Sci, 2022, 1508:23-34. [44] Ruijter BJ, Keijzer HM, Tjepkema-Cloostermans MC, Blans MJ, Beishuizen A, Tromp SC, Scholten E, Horn J, van Rootselaar AF, Admiraal MM, van den Bergh WM, Elting JJ, Foudraine NA, Kornips FHM, van Kranen-Mastenbroek VHJM, Rouhl RPW, Thomeer EC, Moudrous W, Nijhuis FAP, Booij SJ, Hoedemaekers CWE, Doorduin J, Taccone FS, van der Palen J, van Putten MJAM, Hofmeijer J; TELSTAR Investigators. Treating rhythmic and periodic EEG patterns in comatose survivors of cardiac arrest[J]. N Engl J Med, 2022, 386:724-734. [45] Phan J, Ramos M, Soares T, Parmar MS. Poststroke seizure and epilepsy:a review of incidence, risk factors, diagnosis, pathophysiology, and pharmacological therapies[J]. Oxid Med Cell Longev, 2022:ID7692215. [46] Peter-Derex L, Philippeau F, Garnier P, André-Obadia N, Boulogne S, Catenoix H, Convers P, Mazzola L, Gouttard M, Esteban M, Fontaine J, Mechtouff L, Ong E, Cho TH, Nighoghossian N, Perreton N, Termoz A, Haesebaert J, Schott AM, Rabilloud M, Pivot C, Dhelens C, Filip A, Berthezène Y, Rheims S, Boutitie F, Derex L. Safety and efficacy of prophylactic levetiracetam for prevention of epileptic seizures in the acute phase of intracerebral haemorrhage (PEACH):a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Neurol, 2022, 21:781-791. [47] Chamberlain JM, Kapur J, Shinnar S, Elm J, Holsti M, Babcock L, Rogers A, Barsan W, Cloyd J, Lowenstein D, Bleck TP, Conwit R, Meinzer C, Cock H, Fountain NB, Underwood E, Connor JT, Silbergleit R; Neurological Emergencies Treatment Trials; Pediatric Emergency Care Applied Research Network Investigators. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT):a double-blind, responsive-adaptive, randomised controlled trial[J]. Lancet, 2020, 395:1217-1224. [48] Nakamura K, Marushima A, Takahashi Y, Mochizuki M, Kimura A, Fukuda Y, Asami M, Nakamoto H, Egawa S, Kaneko J, Unemoto K, Kondo Y, Yonekawa C, Uchida M, Hoshiyama E, Yamada T, Maruo K, Ishikawa E, Matsumaru Y, Inoue Y; IENE ECT with the LIFE Study Group. Levetiracetam versus fosphenytoin as a second-line treatment after diazepam for adult convulsive status epilepticus:a multicentre non-inferiority randomised control trial[J]. J Neurol Neurosurg Psychiatry, 2023, 94:42-48. [49] Tabaee Damavandi P, Fabin N, Giossi R, Matricardi S, Del Giovane C, Striano P, Meletti S, Brigo F, Trinka E, Lattanzi S. Efficacy and safety of fenfluramine in epilepsy:a systematic review and meta-analysis[J]. Neurol Ther, 2023, 12:669-686. [50] Knupp KG, Scheffer IE, Ceulemans B, Sullivan JE, Nickels KC, Lagae L, Guerrini R, Zuberi SM, Nabbout R, Riney K, Shore S, Agarwal A, Lock M, Farfel GM, Galer BS, Gammaitoni AR, Davis R, Gil-Nagel A. Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox-Gastaut syndrome:a randomized clinical trial[J]. JAMA Neurol, 2022, 79:554-564. [51] Knight EMP, Amin S, Bahi-Buisson N, Benke TA, Cross JH, Demarest ST, Olson HE, Specchio N, Fleming TR, Aimetti AA, Gasior M, Devinsky O; Marigold Trial Group. Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder:results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial[J]. Lancet Neurol, 2022, 21:417-427. [52] Dalic LJ, Warren AEL, Bulluss KJ, Thevathasan W, Roten A, Churilov L, Archer JS. DBS of thalamic centromedian nucleus for Lennox-Gastaut syndrome (ESTEL Trial)[J]. Ann Neurol, 2022, 91:253-267. [53] Qiu Y, O'Neill N, Maffei B, Zourray C, Almacellas-Barbanoj A, Carpenter JC, Jones SP, Leite M, Turner TJ, Moreira FC, Snowball A, Shekh-Ahmad T, Magloire V, Barral S, Kurian MA, Walker MC, Schorge S, Kullmann DM, Lignani G. On-demand cell-autonomous gene therapy for brain circuit disorders[J]. Science, 2022, 378:523-532. [54] Zhang L, Wang Y. Gene therapy in epilepsy[J]. Biomed Pharmacother, 2021, 143:112075. [55] Paul B, Montoya G. CRISPR-Cas12a:functional overview and applications[J]. Biomed J, 2020, 43:8-17. |